CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors
July 12 2022 - 9:00AM
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company
leveraging the power of the mitochondria and the peptides encoded
in its genome to develop potential breakthrough therapeutics
targeting chronic and age-related diseases, today announced the
appointment of Effie Tozzo, Ph.D. as an independent director on the
company’s Board, effective July 11, 2022. Dr. Tozzo brings
extensive research and development experience at both established
pharmaceutical and innovative biotechnology companies.
"We are delighted to add Dr. Tozzo to our Board
and will tap into her considerable expertise in advancing
preclinical assets to the clinic and building robust pipelines,"
said David Greenwood, Chairman of CohBar. "Effie’s deep research
and development experience will provide useful insights as we
continue to look to the mitochondrial genome as a potential source
for novel therapeutics. Her perspective will help inform the
continued progress in our preclinical and clinical programs."
“I look forward to joining CohBar’s Board at
this exciting time as the company is working towards moving a
second candidate into the clinic,” stated Dr. Tozzo. “CohBar’s
Mito+ platform and novel approach to drug discovery have potential
utility in a wide range of therapeutic indications. I am pleased to
contribute to the advancement of the company’s pipeline to benefit
patients in need of new therapies to treat life-threatening
conditions like IPF.”
Dr. Tozzo is currently Chief Scientific Officer
at Avilar Therapeutics, a biotechnology company creating a broad
and diverse pipeline of extracellular protein degraders as
first-in-class medicines for the treatment of serious diseases. As
a leader in drug discovery, translational sciences and medicine,
Dr. Tozzo has over 26 years of experience in leadership roles in
biotech/startups and large pharma organizations. She has initiated
and progressed discovery programs to the clinic by building and
effectively leading teams in preclinical biology, chemistry,
pharmacology, DMPK, safety and biomarker studies in various disease
indications.
Over the past 8 years, Dr. Tozzo served at
Cellarity (a Flagship Pioneering company) as Senior Vice President,
Drug Development and Head of R&D and as Senior Vice President,
Translational Sciences at Mitobridge (acquired by Astellas),
building teams and strong program pipelines, scientifically leading
financing campaigns and pharma partnerships and supporting clinical
teams through Phase 1 and clinical proof of concept
studies.
Earlier in her career, Dr. Tozzo held leading
positions at Merck, Roche, BMS, Millennium, Chiron and ErgoScience.
She received her PhD in Molecular and Cellular Endocrinology from
the University XI in Paris, France, completed her post-doctoral
training in the Endocrine Division at Beth Israel/Harvard Medical
School in Boston and has authored over 40 peer-reviewed
publications and patents.
About CohBar
CohBar (NASDAQ: CWBR) is a clinical-stage
biotechnology company leveraging the power of the mitochondria and
the peptides encoded in its genome to develop potential
breakthrough therapeutics targeting chronic and age-related
diseases with limited to no treatment options. CohBar has assembled
the leading position in exploring the mitochondrial genome and its
utility for the development of novel therapeutics, including
world-renowned expertise in mitochondrial biology, a broad
intellectual property estate, key opinion leaders and disciplined
drug discovery and development processes. CohBar is utilizing its
Mito+ platform to identify and develop modified versions of natural
peptides called analogs to treat a variety of serious conditions,
with a focus on diseases involving inflammation and fibrosis.
For additional company information, please visit
www.cohbar.com and engage with us on LinkedIn.
Forward-Looking Statements
This news release contains forward-looking
statements that are not historical facts within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements are based only on our current beliefs, expectations and
assumptions regarding the future of our business, future plans and
strategies, projections, anticipated events and other future
conditions. In some cases you can identify these statements by
forward-looking words such as “believe,” “may,” “will,” “estimate,”
“continue,” “anticipate,” “intend,” “could,” “should,” “would,”
“project,” “plan,” “expect,” “goal,” “seek,” “future,” “likely” or
the negative or plural of these words or similar expressions.
Examples of such forward-looking statements include but are not
limited to statements regarding timing and anticipated outcomes of
research and clinical trials for our product candidates;
expectations regarding the growth of therapies developed from
modified mitochondrial peptides as a significant future class of
drug products; and statements regarding anticipated
therapeutic properties and potential of our mitochondrial peptide
analogs and other potential therapies. You are cautioned that such
statements are not guarantees of future performance and that actual
results or developments may differ materially from those set forth
in these forward-looking statements. Factors that could cause
actual results to differ materially from these forward-looking
statements include: our ability to successfully advance drug
discovery and development programs, including the delay or
termination of ongoing clinical trials and the timing of
announcements and updates relating to our clinical trials and
related data; our possible inability to mitigate the prevalence
and/or persistence of the injection site reactions, or the
possibility of other developments affecting the viability of CB4211
or CB5138-3 as a clinical candidate or its commercial potential;
results that are different from earlier data results including less
favorable results that may not support further clinical
development; our ability to raise additional capital when necessary
to continue our operations; our ability to recruit and retain key
management and scientific personnel; the risk that our intellectual
property may not be adequately protected; our ability to establish
and maintain partnerships with corporate and industry partners; and
risks related to the impact on our business of the COVID-19
pandemic or similar public health crises. Additional assumptions,
risks and uncertainties are described in detail in our registration
statements, reports and other filings with the Securities and
Exchange Commission and applicable Canadian securities regulators,
which are available on our website, and at www.sec.gov
or www.sedar.com.
You are cautioned that such statements are not
guarantees of future performance and that our actual results may
differ materially from those set forth in the forward-looking
statements. The forward-looking statements and other information
contained in this news release are made as of the date hereof and
CohBar does not undertake any obligation to update publicly or
revise any forward-looking statements or information, whether as a
result of new information, future events or otherwise, unless so
required by applicable securities laws. Nothing herein shall
constitute an offer to sell or the solicitation of an offer to buy
any securities.
Contacts: Jordyn TaraziDirector of Investor
RelationsCohBar, Inc.(650) 445-4441Jordyn.tarazi@cohbar.com
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Aug 2024 to Sep 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Sep 2023 to Sep 2024